1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. SoftOx Solutions AS
  6. News
  7. Summary
    SOFTX   NO0010811961

SOFTOX SOLUTIONS AS

(SOFTX)
Real-time Oslo Bors  -  05/20 10:19:32 am EDT
42.00 NOK   -2.33%
05/19SOFTOX SOLUTIONS AS : Announces positive phase 1 results for softox inhalation solution (sis)
AQ
05/18SoftOx Solutions AS Announces Positive Phase 1 Results for SoftOx Inhalation Solution
CI
05/18SOFTOX SOLUTIONS AS : to attend and host an educational symposium at the European Wound Management Association Conference
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SOFTX: Ex. Right to receive subscription rights in potential repair offering

12/16/2021 | 01:31am EDT
Issuer name: SoftOx Solutions AS
Ex. Date: 16 December 2021
Type of corporate action: potential repair offering 

This information is published in accordance with the requirements of the
Euronext Growth Oslo RB II - Issuer Rules 

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SotfOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange

All news about SOFTOX SOLUTIONS AS
05/19SOFTOX SOLUTIONS AS : Announces positive phase 1 results for softox inhalation solution (s..
AQ
05/18SoftOx Solutions AS Announces Positive Phase 1 Results for SoftOx Inhalation Solution
CI
05/18SOFTOX SOLUTIONS AS : to attend and host an educational symposium at the European Wound Ma..
AQ
05/12SOFTOX SOLUTIONS AS : Annual general meeting held
AQ
05/11SOFTOX SOLUTIONS AS : The SBE-01 phase 1 clinical study enters the final phase 1b
AQ
05/10SoftOx Solutions AS Announces the Last Patient Completes the Last Single-Dose Cohort of..
CI
05/05SOFTOX SOLUTIONS AS : Notice of Annual General Meeting
AQ
05/04SOFTOX SOLUTIONS AS : Annual Report 2021
AQ
04/28SOFTOX SOLUTIONS AS : Announces advancement into next phase (1b) in the SBE project
AQ
04/28Softox Solutions AS Announces Advancement into Next Phase (1B) in the SBE Project
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 434 M 44,5 M 44,5 M
EV / Sales -1
EV / Sales 0
Nbr of Employees 23
Free-Float 59,0%
Chart SOFTOX SOLUTIONS AS
Duration : Period :
SoftOx Solutions AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOFTOX SOLUTIONS AS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Geir Hermod Almås Chief Executive Officer
Kristine Mundal Rød Chief Financial Officer
Melvin Teigen Chairman
Glenn Gundersen Medical Director
Magnus Mustafa Fazli Head-Science & Research
Sector and Competitors
1st jan.Capi. (M$)
SOFTOX SOLUTIONS AS-25.00%44
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612